Literature DB >> 3549471

Immunotherapy for cancer: the use of lymphokine activated killer (LAK) cells.

E A Fagan, A L Eddleston.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3549471      PMCID： PMC1432985          DOI： 10.1136/gut.28.2.113

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  26 in total

1.  Phase I study of the adoptive immunotherapy of human cancer with lectin activated autologous mononuclear cells.

Authors:  A Mazumder; T J Eberlein; E A Grimm; D J Wilson; A M Keenan; R Aamodt; S A Rosenberg
Journal:  Cancer       Date:  1984-02-15       Impact factor: 6.860

2.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

3.  Adoptive immunotherapy of cancer: accomplishments and prospects.

Authors:  S A Rosenberg
Journal:  Cancer Treat Rep       Date:  1984-01

4.  The fate of interleukin-2 after in vivo administration.

Authors:  J H Donohue; S A Rosenberg
Journal:  J Immunol       Date:  1983-05       Impact factor: 5.422

5.  The in vivo distribution of autologous human and murine lymphoid cells grown in T cell growth factor (TCGF): implications for the adoptive immunotherapy of tumors.

Authors:  M T Lotze; B R Line; D J Mathisen; S A Rosenberg
Journal:  J Immunol       Date:  1980-10       Impact factor: 5.422

6.  In vitro growth of murine T cells. V. The isolation and growth of lymphoid cells infiltrating syngeneic solid tumors.

Authors:  I Yron; T A Wood; P J Spiess; S A Rosenberg
Journal:  J Immunol       Date:  1980-07       Impact factor: 5.422

7.  Systemic administration of interleukin-2 in humans.

Authors:  M T Lotze; R J Robb; S O Sharrow; L W Frana; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1984-10

8.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

9.  Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells.

Authors:  E A Grimm; K M Ramsey; A Mazumder; D J Wilson; J Y Djeu; S A Rosenberg
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

10.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
View more
  6 in total

Review 1.  Induction of T Cell Senescence by Cytokine Induced Bystander Activation.

Authors:  Attiya A Abbas; Arne N Akbar
Journal:  Front Aging       Date:  2021-07-09

2.  Lysis of colonic epithelial cells by allogeneic mononuclear and lymphokine activated killer cells derived from peripheral blood and intestinal mucosa: evidence against a pathogenic role in inflammatory bowel disease.

Authors:  P R Gibson; E van de Pol; W Pullman; W F Doe
Journal:  Gut       Date:  1988-08       Impact factor: 23.059

3.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

4.  Retrospective analysis of the efficacy of adjuvant cytokine-induced killer cell immunotherapy combined with chemotherapy in colorectal cancer patients after surgery.

Authors:  Xiao Li; Haodong Zhou; Wenwen Huang; Xuejuan Wang; Mingyao Meng; Zongliu Hou; Liwei Liao; Weiwei Tang; Yanhua Xie; Ruotian Wang; Haidong Yu; Liqiong Wang; Huirong Zhu; Wenju Wang; Jing Tan; Ruhong Li
Journal:  Clin Transl Immunology       Date:  2022-01-18

Review 5.  Sarcoma immunotherapy: past approaches and future directions.

Authors:  S P D'Angelo; W D Tap; G K Schwartz; R D Carvajal
Journal:  Sarcoma       Date:  2014-03-20

6.  The NKG2D-IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies.

Authors:  Tobias Ruck; Stefan Bittner; Ali Maisam Afzali; Kerstin Göbel; Sarah Glumm; Peter Kraft; Claudia Sommer; Christoph Kleinschnitz; Corinna Preuße; Werner Stenzel; Heinz Wiendl; Sven G Meuth
Journal:  Oncotarget       Date:  2015-12-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.